Immuneering Corporation
NASDAQ · us_market
No AI insight generated yet for this ticker.
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 9.70M | $51.11M | 0.00% | Unchanged | 2026-03-31 |
| StateStreet | passive | 268.5K | $1.42M | 0.00% | Trimmed-88.8% | 2026-03-31 |
| TwoSigma | quant | 244.8K | $1.29M | 0.00% | Added+18.2% | 2026-03-31 |
| Wellington | fundamental | 156.4K | $824.36K | 0.00% | New | 2026-03-31 |
| RenTech | quant | 72.9K | $384.05K | 0.00% | Trimmed-52.2% | 2026-03-31 |
| TRowePrice | fundamental | 1.83M | $9.64K | 0.00% | Trimmed-8.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.27 | — | — |
| 2026-05-15 | -0.25 | -0.21 | +16.67% |
| 2026-03-06 | -0.31 | -0.18 | +42.25% |
| 2025-11-12 | -0.39 | -0.38 | +2.15% |
| 2025-08-13 | -0.40 | -0.40 | -0.50% |
| 2025-05-05 | -0.58 | -0.42 | +28.21% |
| 2025-03-20 | -0.44 | -0.58 | -30.34% |
| 2024-11-13 | -0.55 | -0.49 | +11.18% |
| 2024-08-06 | -0.53 | -0.47 | +10.76% |
| 2024-05-07 | -0.50 | -0.49 | +2.56% |
| 2024-03-01 | -0.48 | -0.52 | -8.98% |
| 2023-11-09 | -0.49 | -0.43 | +11.99% |
| 2023-08-03 | -0.53 | -0.43 | +18.21% |
| 2023-05-04 | -0.56 | -0.51 | +8.23% |
| 2023-03-06 | -0.56 | -0.50 | +11.24% |
| 2022-11-10 | -0.48 | -0.49 | -1.73% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| IMRX | +7.45% | +16.57% | -12.31% | +237.43% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +4.48% | +21.20% | -8.87% | +224.74% |